Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center Raja M. Flores, MD, Maureen Zakowski, MD, Ennapadam.

Slides:

Advertisements

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Advertisements

The prognostic importance of the number of involved lymph nodes in esophageal cancer: Implications for revisions of the American Joint Committee on Cancer.

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD

Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia Arman Hasani, MBBS, FRACP, John M. Alvarez,

Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center Raja M. Flores, MD, Maureen Zakowski, MD, Ennapadam.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma Clive J. Kelty, MB, ChB, PhD, FRCSEd,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma Vivek Verma, MD, Christopher A. Ahern,

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Meta-Analysis of Survival After Pleurectomy Decortication Versus Extrapleural Pneumonectomy in Mesothelioma Emanuela Taioli, MD, PhD, Andrea S. Wolf,

A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma Isabelle Opitz, MD, Martina Friess,

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

John E. Pilling, FRCS (CTh), Michael E

Frank Detterbeck, MD Journal of Thoracic Oncology

Nael Martini, MDa, Manjit S. Bains, MDa, Michael E

The prognostic importance of the number of involved lymph nodes in esophageal cancer: Implications for revisions of the American Joint Committee on Cancer.

Pulmonary Resection for Metastatic Gastric Cancer

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

Frequency of Use and Predictors of Cancer-Directed Surgery in the Management of Malignant Pleural Mesothelioma in a Community-Based (Surveillance, Epidemiology,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Clinical Outcomes and Prognosis of Recurrent Thymoma Management

Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma Fauzia Shaikh, MD, Marjorie G. Zauderer,

Feiran Lou, MD, MS, Camelia S. Sima, MD, MS, Prasad S

High SUVmax on FDG-PET Indicates Pleomorphic Subtype in Epithelioid Malignant Pleural Mesothelioma: Supportive Evidence to Reclassify Pleomorphic as Nonepithelioid.

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Onkar V. Khullar, MD, Yuan Liu, PhD, Theresa Gillespie, PhD, Kristin A

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Valerie W Rusch, MD, Ennapadam S Venkatraman, PhD

Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients Raja.

Patterns of Failure, Toxicity, and Survival after Extrapleural Pneumonectomy and Hemithoracic Intensity-Modulated Radiation Therapy for Malignant Pleural.

Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II Study Gunnar Hillerdal, MD, PhD, Jens.

Nabil P. Rizk, MD, Venkatraman E. Seshan, PhD, Manjit S

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Patterns of Local and Nodal Failure in Malignant Pleural Mesothelioma After Extrapleural Pneumonectomy and Photon-Electron Radiotherapy Vishal Gupta,

The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: Implications for revision of the.

Clinical Relevance of Our Multimodality Prognostic Score

Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma Loïc.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed.

In Arrayed Ranks: Array Technology in the Study of Mesothelioma

Ethnic Differences in the Management of Lung Cancer in New Zealand

International Thymic Malignancies Interest Group: A Way Forward

Linda L. Garland, MD, Kari Chansky, MS, Antoinette J

Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma

A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma Valerie W. Rusch, MDa, Kenneth.

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Positron emission tomography predicts survival in malignant pleural mesothelioma Raja M. Flores, MD, Timothy Akhurst, MD, Mithat Gonen, PhD, Maureen Zakowski,

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Raja M. Flores, MD The Journal of Thoracic and Cardiovascular Surgery

Raja M. Flores, MD, Bernard J

Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database Valerie W. Rusch, MD, Dorothy Giroux, Catherine.

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Nael Martini, MDa, Valerie W. Rusch, MDa, Manjit S. Bains, MDa, Mark G

Outcome after Pulmonary Metastasectomy: Analysis of 5 Years Consecutive Surgical Resections 2002–2006 Kåre Hornbech, MD, Jesper Ravn, MD, Daniel Andreas.

Michael J. Weyant, MD, Manjit S

Thirty-Day Mortality Underestimates the Risk of Early Death After Major Resections for Thoracic Malignancies Robert R. McMillan, MD, MPH, Alexandra Berger,

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center Raja M. Flores, MD, Maureen Zakowski, MD, Ennapadam Venkatraman, PhD, Lee Krug, MD, Kenneth Rosenzweig, MD, Joseph Dycoco, BA, Catherine Lee, MD, Cindy Yeoh, MD, Manjit Bains, MD, Valerie Rusch, MD Journal of Thoracic Oncology Volume 2, Issue 10, Pages 957-965 (October 2007) DOI: 10.1097/JTO.0b013e31815608d9 Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Overall survival by histology (p < 0.001). Journal of Thoracic Oncology 2007 2, 957-965DOI: (10.1097/JTO.0b013e31815608d9) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Survival by pathologic stages I–II versus 3–4 (p < 0.001). Journal of Thoracic Oncology 2007 2, 957-965DOI: (10.1097/JTO.0b013e31815608d9) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Survival by clinical stages 1–2 versus 3–4 (p < 0.01). Journal of Thoracic Oncology 2007 2, 957-965DOI: (10.1097/JTO.0b013e31815608d9) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Survival by gender (p < 0.001). Journal of Thoracic Oncology 2007 2, 957-965DOI: (10.1097/JTO.0b013e31815608d9) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Survival by smoking history (p = 0.002). Journal of Thoracic Oncology 2007 2, 957-965DOI: (10.1097/JTO.0b013e31815608d9) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 Survival by history of asbestos exposure (p < 0.001). Journal of Thoracic Oncology 2007 2, 957-965DOI: (10.1097/JTO.0b013e31815608d9) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 7 Survival by laterality (p = 0.001). Journal of Thoracic Oncology 2007 2, 957-965DOI: (10.1097/JTO.0b013e31815608d9) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 8 Survival by symptom presentation (p = 0.02). Journal of Thoracic Oncology 2007 2, 957-965DOI: (10.1097/JTO.0b013e31815608d9) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 9 Survival by surgical resection, extrapleural pneumonectomy (EPP), and pleurectomy/decortication (P/D) versus ET (exploratory thoracotomy) and nonoperative (p = 0.001). Journal of Thoracic Oncology 2007 2, 957-965DOI: (10.1097/JTO.0b013e31815608d9) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 10 Survival by multimodality treatment versus surgical resection alone (p = 0.001). EPP, extrapleural pneumonectomy; P/D, pleurectomy/decortication. Journal of Thoracic Oncology 2007 2, 957-965DOI: (10.1097/JTO.0b013e31815608d9) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions